[{"orgOrder":0,"company":"GSK","sponsor":"Immutep","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IMP731","moa":"LAG3 cell","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GSK \/ Immutep","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Immutep"},{"orgOrder":0,"company":"Immutep","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"IMP731","moa":"LAG3 cell","graph1":"Immunology","graph2":"Phase II","graph3":"Immutep","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Immutep \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Immutep \/ GSK"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"IMP731","moa":"Lymphocyte activation gene 3 protein (LAG3)","graph1":"Undisclosed","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"IMP731","moa":"Lymphocyte activation gene 3 protein (LAG3)","graph1":"Dermatology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"GSK \/ Parexel","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Parexel"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"IMP731","moa":"Lymphocyte activation gene 3 protein (LAG3)","graph1":"Immunology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"}]